Browsing Tag
amyotrophic lateral sclerosis
15 posts
Neurizon Therapeutics (ASX: NUZ) just crossed the threshold every ALS biotech dreams about. Now the hard part starts.
Neurizon Therapeutics (ASX: NUZ) doses first ALS patient in the HEALEY Platform Trial. What the Phase 2/3 design means for investors and the sector. Read more.
NeuroSense Therapeutics (NASDAQ: NRSN) extends PrimeC exclusivity to 2042 with Australian patent as Phase 3 focus intensifies
Find out how NeuroSense Therapeutics’ Australian patent grant strengthens PrimeC’s long-term outlook as the ALS program advances toward Phase 3.
AL-S Pharma’s AP-101 prolongs survival and delays ventilator use in ALS Phase 2 trial
AL-S Pharma’s AP-101 showed survival and biomarker gains in ALS Phase 2 study. Find out what this means as the firm prepares for Phase 3.
NeuroSense Therapeutics (NASDAQ: NRSN) gets FDA nod for pivotal ALS trial: Is PrimeC nearing commercial breakthrough?
NeuroSense gains FDA clearance for Phase 3 ALS trial of PrimeC, with patient enrollment and global execution plans underway. Find out what comes next.
FDA delay shifts Neurizon Therapeutics (ASX: NUZ) ALS trial start — Can Q4 still deliver a win?
FDA delays decision on Neurizon’s NUZ-001 ALS trial to October, but manufacturing, regulatory, and trial readiness milestones keep Q4 start within reach.
Neurizon Therapeutics secures global licence from Elanco to fast-track NUZ-001 commercialisation
Find out how Neurizon’s global licence with Elanco is accelerating ALS therapy NUZ-001 and de-risking its path to market entry and clinical trials.
Zydus Lifesciences gets FDA approval for Phase 2b ALS trial of Usnoflast
Zydus Lifesciences, a global leader in pharmaceutical innovation, has received approval from the United States Food and Drug…
Athira Pharma stock nosedives after Alzheimer’s drug trial results disappoint
Athira Pharma’s stock plunged by 75% after the company announced that its Phase 2/3 LIFT-AD clinical trial for…
Amylyx Pharmaceuticals’ AMX0035 misses primary and secondary endpoints in ALS study
Cambridge, Massachusetts-based Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX), a key player in the pharmaceutical industry, announced today the top-line…
Nura Bio kicks off Phase 1 clinical trials for SARM1 inhibitor NB-4746
Nura Bio, a leading biopharmaceutical company specializing in neuroprotective, small molecule therapies, announced today the initiation of Phase…